By Dan Schell, Chief Editor, Clinical Leader
Whenever someone brings up the topic of change, especially in relation to the pandemic, inevitably there is some mention of the word technology, too (e.g., Zoom calls). If we're talking about the biopharma industry, then usually conversations including these two words also are peppered with terms like slow or late adopter. Sure, there are plenty of exceptions to this rule, but overall, we're not exactly known to be cutting edge in terms of technology adoption. But according to a recent report by Deloitte, that sentiment may be changing.